• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经尿道注射乙烯乙烯醇(Tegress)后的长期疗效及患者满意度:一项双中心研究。

Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress) injections: a two-centre study.

作者信息

Kuhn Annette, Stadlmayr Werner, Sohail Amara, Monga Ash

机构信息

Frauenklinik, Inselspital, Bern, Switzerland.

出版信息

Int Urogynecol J Pelvic Floor Dysfunct. 2008 Apr;19(4):503-7. doi: 10.1007/s00192-007-0479-5. Epub 2007 Oct 23.

DOI:10.1007/s00192-007-0479-5
PMID:17955152
Abstract

Tegress is ethylene vinyl alcohol which is non-allergenic and permanent. The aim of the study was to evaluate efficacy, feasibility and safety of transurethral Tegress in women with urodynamic stress incontinence in a two-centre setting. Approximately 33 female patients with urodynamic stress incontinence were prospectively included in the study. Preoperatively, the patient's history, gynaecological examination and multichannel urodynamics were performed. On follow-up, the patient was asked to use a visual analogue scale to measure her contentness and underwent uroflowmetry and a cough test. Median follow up was 51 months. About 15 women considered themselves as completely continent, and 23 (69%) were either satisfied or very satisfied. Pad test was positive in 18 (54.5%) patients, and cough test was positive in 20 (60.6%). Patients' satisfaction did not correlate with objective dryness. Ethylene vinyl alcohol is a bulking agent with a success rate of approximately 45% after 51 months.

摘要

泰格雷斯是一种非致敏性且永久性的乙烯-乙烯醇共聚物。本研究的目的是在两个中心评估经尿道使用泰格雷斯治疗女性压力性尿失禁的疗效、可行性和安全性。约33例压力性尿失禁女性患者前瞻性纳入本研究。术前进行患者病史、妇科检查和多通道尿动力学检查。随访时,要求患者使用视觉模拟量表测量其满意度,并进行尿流率测定和咳嗽试验。中位随访时间为51个月。约15名女性认为自己完全控尿,23名(69%)患者满意或非常满意。18名(54.5%)患者护垫试验阳性,20名(60.6%)患者咳嗽试验阳性。患者满意度与客观干燥情况无关。乙烯-乙烯醇共聚物是一种填充剂,51个月后的成功率约为45%。

相似文献

1
Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress) injections: a two-centre study.经尿道注射乙烯乙烯醇(Tegress)后的长期疗效及患者满意度:一项双中心研究。
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Apr;19(4):503-7. doi: 10.1007/s00192-007-0479-5. Epub 2007 Oct 23.
2
Bulking agents: an analysis of 500 cases and review of the literature.填充剂:500例病例分析及文献综述
Int Urogynecol J. 2013 Feb;24(2):241-7. doi: 10.1007/s00192-012-1834-8. Epub 2012 Jun 16.
3
Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinence.乙烯-乙烯醇共聚物作为压力性尿失禁男性尿道内填充剂的并发症
Urology. 2008 Apr;71(4):662-5. doi: 10.1016/j.urology.2007.10.016. Epub 2008 Feb 15.
4
Urethral injection therapy for urinary incontinence in women.女性尿失禁的尿道注射治疗
Cochrane Database Syst Rev. 2012 Feb 15(2):CD003881. doi: 10.1002/14651858.CD003881.pub3.
5
[Transurethral injection of polyacrylamide hydrogel (Bulkamid®) for the treatment of female stress urinary incontinence and changes in the cure rate over time].[经尿道注射聚丙烯酰胺水凝胶(Bulkamid®)治疗女性压力性尿失禁及治愈率随时间的变化]
Ceska Gynekol. 2013 Dec;78(6):554-9.
6
Where should bulking agents for female urodynamic stress incontinence be injected?治疗女性压力性尿失禁的填充剂应注射在何处?
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jun;19(6):817-21. doi: 10.1007/s00192-007-0535-1.
7
Collagen for female genuine stress incontinence after a minimum 2-year follow-up.
Br J Urol. 1997 Nov;80(5):757-61. doi: 10.1046/j.1464-410x.1997.00465.x.
8
Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review.用于治疗女性压力性尿失禁的尿道内填充剂:一项系统评价
Int Urogynecol J. 2017 Sep;28(9):1275-1284. doi: 10.1007/s00192-017-3278-7. Epub 2017 Feb 21.
9
Periurethral injection therapy for urinary incontinence in women.女性尿失禁的尿道周围注射疗法
Cochrane Database Syst Rev. 2007 Jul 18(3):CD003881. doi: 10.1002/14651858.CD003881.pub2.
10
An adjustable sling in the management of recurrent urodynamic stress incontinence after previous failed midurethral tape.经尿道中段吊带术失败后治疗复发性尿动力学压力性尿失禁的可调吊带。
Neurourol Urodyn. 2010 Apr;29(4):573-7. doi: 10.1002/nau.20793.

引用本文的文献

1
Animal models, treatment options, and biomaterials for female stress urinary incontinence.女性压力性尿失禁的动物模型、治疗方案及生物材料
Front Bioeng Biotechnol. 2024 Aug 29;12:1414323. doi: 10.3389/fbioe.2024.1414323. eCollection 2024.
2
Urethrocutaneous fistula after use of Tegress bulking agent: Case report and review of the literature.使用Tegress填充剂后发生尿道皮肤瘘:病例报告及文献综述
Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E833-6. doi: 10.5489/cuaj.481.
3
Bulking agents: an analysis of 500 cases and review of the literature.

本文引用的文献

1
Periurethral injection therapy for urinary incontinence in women.女性尿失禁的尿道周围注射疗法
Cochrane Database Syst Rev. 2007 Jul 18(3):CD003881. doi: 10.1002/14651858.CD003881.pub2.
2
Ethylene vinyl alcohol copolymer erosions after use as a urethral bulking agent.作为尿道填充剂使用后乙烯-乙烯醇共聚物的侵蚀情况
Obstet Gynecol. 2007 Feb;109(2 Pt2):490-2. doi: 10.1097/01.AOG.0000252261.55000.b2.
3
Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.用于女性压力性尿失禁的Macroplastique植入系统:长期随访
填充剂:500例病例分析及文献综述
Int Urogynecol J. 2013 Feb;24(2):241-7. doi: 10.1007/s00192-012-1834-8. Epub 2012 Jun 16.
4
Nonsurgical outpatient therapies for the management of female stress urinary incontinence: long-term effectiveness and durability.女性压力性尿失禁管理的非手术门诊治疗:长期有效性和持久性
Adv Urol. 2011;2011:176498. doi: 10.1155/2011/176498. Epub 2011 Jun 23.
5
Urethral bulking agents: techniques and outcomes.尿道填充剂:技术与效果
Curr Urol Rep. 2009 Sep;10(5):396-400. doi: 10.1007/s11934-009-0062-3.
6
Complications of Tegress injections.Tegress注射的并发症。
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jan;20(1):127; author reply 129. doi: 10.1007/s00192-008-0674-z. Epub 2008 Jul 5.
J Endourol. 2006 Dec;20(12):1082-6. doi: 10.1089/end.2006.20.1082.
4
The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency.乙烯-乙烯醇共聚物作为内在性尿道缺损女性尿道内填充剂的安全性和有效性。
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Aug;18(8):869-73. doi: 10.1007/s00192-006-0251-2. Epub 2006 Nov 14.
5
Which questionnaire? A psychometric evaluation of three patient-based outcome measures used to assess surgery for stress urinary incontinence.哪种问卷?对用于评估压力性尿失禁手术的三种基于患者的结局指标的心理测量学评价
Neurourol Urodyn. 2007;26(1):123-8. doi: 10.1002/nau.20303.
6
Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness.泰格雷斯商标尿道植入物三期临床经验及产品独特性。
Rev Urol. 2005;7 Suppl 1(Suppl 1):S22-6.
7
Crohn's disease of the esophagus: treatment of an esophagobronchial fistula with the novel liquid embolic polymer "onyx".
Z Gastroenterol. 2006 Jul;44(7):599-602. doi: 10.1055/s-2006-926644.
8
Do early injections of bulking agents following radical prostatectomy improve early continence?
World J Urol. 2005 Nov;23(5):338-42. doi: 10.1007/s00345-005-0010-x. Epub 2005 Nov 1.
9
Transvenous injection of Onyx for casting of the cavernous sinus for the treatment of a carotid-cavernous fistula.经静脉注射Onyx用于海绵窦铸型以治疗颈内动脉海绵窦瘘。
Neuroradiology. 2004 Dec;46(12):1012-5. doi: 10.1007/s00234-004-1244-9. Epub 2004 Nov 9.
10
Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence.一种新型系统(使用植入器装置的NASHA/Dx共聚物)治疗压力性尿失禁的疗效和安全性。
Urology. 2004 Aug;64(2):276-81. doi: 10.1016/j.urology.2004.03.017.